Pressure BioSciences, Inc. (OTCMKTS:PBIO – Get Free Report) saw a large drop in short interest in the month of June. As of June 15th, there was short interest totalling 8,100 shares, a drop of 69.4% from the May 31st total of 26,500 shares. Based on an average trading volume of 132,300 shares, the short-interest ratio is currently 0.1 days.
Pressure BioSciences Price Performance
Shares of PBIO stock traded up $0.01 during midday trading on Thursday, reaching $0.14. 68,500 shares of the company traded hands, compared to its average volume of 73,407. The firm’s 50 day simple moving average is $0.20 and its two-hundred day simple moving average is $0.25. Pressure BioSciences has a 1-year low of $0.11 and a 1-year high of $0.80. The firm has a market cap of $4.97 million, a PE ratio of -0.09 and a beta of -0.21.
Pressure BioSciences (OTCMKTS:PBIO – Get Free Report) last posted its earnings results on Friday, June 7th. The company reported ($0.30) earnings per share (EPS) for the quarter. The company had revenue of $0.31 million during the quarter.
About Pressure BioSciences
Pressure BioSciences, Inc develops and sells pressure-based platform solutions in the North America, Europe, and Asia. The company's pressure cycling technology (PCT) technology uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to control the actions of molecules in biological samples, including cells and tissues from human, animal, plant, and microbial sources.
Recommended Stories
- Five stocks we like better than Pressure BioSciences
- Stock Market Holidays 2022-2025 – Here’s When the NYSE and NASDAQ Will be Closed
- BlackBerry Stock: Strong Earnings, Profitability Challenges Ahead
- Top Stocks Investing in 5G Technology
- Progress Software Stock Back in the Green After Beating Forecasts
- Most active stocks: Dollar volume vs share volume
- Goldman Sachs Raises Stock Target for Affirm: Key Insights
Receive News & Ratings for Pressure BioSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pressure BioSciences and related companies with MarketBeat.com's FREE daily email newsletter.